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Abstract (215 words) 
Clear cell renal cell carcinomas (ccRCC) are characterized by inactivation of von Hippel-Lindau (VHL) 
gene and intracellular lipid accumulation by unknown pathomechanism. The immunochemical analysis 
of 356 RCCs revealed high abundance of apolipoproteins apoA-I and apoB as well as scavenger receptor 
BI (SR-BI) in the clear cell RCC subtype. Given the characteristic loss of VHL function in ccRCC, we 
used VHL-defective and VHL-proficient cells to study the potential influence of VHL on lipoprotein 
uptake. VHL-defective patient-derived ccRCC cells and cell lines (786O and RCC4) showed enhanced 
uptake as well as less re-secretion and degradation of radio-iodinated high and low density lipoproteins 
(125I-HDL and 125I-LDL) compared to the VHL-proficient cells. The ccRCC cells showed enhanced 
VEGF and SR-BI expression compared to normal kidney epithelial cells. Uptake of 125I-HDL and 125I-
LDL by patient-derived normal kidney epithelial cells as well as VHL-re-expressing ccRCC cell lines 
786-O-VHL and RCC4-O-VHL cells was strongly enhanced by VEGF treatment. The knock-down of 
VEGF co-receptor neuropilin (NRP1) as well as blocking of SR-BI significantly reduced the uptake of 
lipoproteins into ccRCC cells in vitro. LDL stimulated proliferation of 786-O cells more potently than 
786-O-VHL cells in a NRP1- and SR-BI- dependent manner. In conclusion, enhanced lipoprotein uptake 
due to increased activities of VEGF/NRP1 and SR-BI promotes lipid accumulation and proliferation of 
VHL-defective ccRCC cells. 
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Introduction 
Classification of renal cell carcinomas (RCC) subtypes is based on histologically predominant 
cytoplasmic features (clear cell RCC, ccRCC), characteristic staining (chromophobe RCC), architectural 
features (papillary RCC) or specific molecular alterations (translocation RCC). CcRCC, received its 
name from the microscopic appearance upon staining of formalin fixed and paraffin embedded (FFPE) 
sections with hematoxylin-eosin (1). The clear appearance of the cytoplasm is due to the accumulation 
of glycogen and lipids that are dissolved during routine processing with deparaffinization of FFPE 
sections using xylene and ethanol. The most prominent lipid stored in renal tumor cells is cholesterol, 
largely in the esterified form (2). The mechanisms for cholesterol accumulation in ccRCC cells is not 
well understood. Three principle pathways have to be considered, two of which have been ruled out 
previously, namely excessive cholesterol synthesis by the finding of decreased rather than increased 
activity of the rate limiting enzyme HMG-CoA reductase (3) as well as abnormal cholesterol efflux (2). 
The third explanation is most likely, excessive uptake of cholesterol from plasma lipoproteins beyond 
the capacity of utilization and processing. However, neither the lipoprotein classes nor the receptors and 
cellular pathways involved are well characterized. CcRCC lacks the low-density lipoprotein receptor 
(LDLR), which is the main entry route for exogenous cholesterol into the majority of cells including 
many tumor cells (4). In contrast, the expression of both the very low-density lipoprotein receptor 
(VLDLR) and scavenger receptor-BI (SR-BI) was found increased in ccRCC compared to the normal 
kidney tissue (5) and to mediate lipid uptake into ccRCC cells from very low density lipoproteins 
(VLDL) and high density lipoproteins (HDL), respectively (5, 6). 
The activity of vascular endothelial growth factor (VEGF) is increased in the majority of ccRCCs (7, 8) 
due to the constitutive activation of hypoxia-inducible factor 1 alpha (HIF-1α) by somatic mutations in 
the von Hippel-Lindau (VHL) tumor suppressor gene. The VHL protein is a component of the E3-
ubiquitin ligase complex that ubiquitylates HIF-1α and HIF-2α for proteasome-mediated degradation 
(7-9). Thus, the loss of VHL function leads to HIF-1α stabilization despite an adequately oxygenated 
tissue microenvironment, which in turn results in uncontrolled activation of HIF-target genes that 
regulate erythropoiesis (erythropoietin), angiogenesis (VEGF), glycolysis (glucose transporters and 
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glycolytic pathway enzymes), and apoptosis (BNIP3)(8-12). We have previously found that VEGF 
promotes the cell surface abundance of SR-BI in endothelial cells and thereby enhances the uptake of 
HDL into endothelial cells (13). Therefore, we hypothesized that increased activities of HIF-1α and 
hence VEGF promote the cell surface expression of SR-BI and thereby uptake of HDL. To test this 
hypothesis, we combined immunohistochemical studies in human renal tumors with experiments in two 
ccRCC model cell lines and patient-derived ccRCC cell cultures.  
Materials and Methods 
Patients, Tissue microarray Construction and Immunohistochemistry  
RCC patients were identified from the database of the Institute of Pathology and Molecular Pathology, 
University Hospital Zurich, Switzerland. All RCCs were histologically re-evaluated by one pathologist 
(H.M.) and selected on the basis of hematoxylin and eosin-stained tissue sections. The patient cohort 
and the construction of tissue microarrays (TMA) of RCC were previously described (14) (15). Tumors 
were staged and histologically classified according to the World Health Organization classification (16). 
Overall survival data were obtained by the Cancer Registry of the Canton Zurich. The clinical and 
pathologic parameters of the tumors on the TMA are summarized in Supplementary Table S1. For some 
cases there was no information available. This study was approved by the local commission of ethics 
(KEK-ZH no. 2011-0072/4). 
TMA sections (2.5 μm) were transferred to glass slides followed by immunohistochemical analysis 
according to the Ventana (Tucson, AZ, USA) automat protocols and antibodies used are listed in 
Supplementary Table S2. The staining intensities were classified as absent (0), weak (1), moderate (2), 
and strong (3). For detailed analysis, TMAs were scanned using the NanoZoomer Digital Slide Scanner 
(Hamamatsu Photonics K.K.). 
Cell culture 
Tissue samples of patients were made available by the Tissue Biobank of the Department of Pathology 
and Molecular Pathology, University Hospital of Zurich, Switzerland upon approval of the local ethics 
commission (KEK-ZH-Nr. 2011-0072 and KEK-ZH-Nr. 2014-0614) and upon patients’ written consent. 
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HE-stained sections of formalin-fixed paraffin-embedded (FFPE) and fresh frozen renal tissue 
specimens were reviewed by a pathologist with specialization in uropathology (H.M).  Sanger 
sequencing was employed to assess the mutation status of the VHL gene (c.341-1G>C) for the ccRCC 
primary tumor and the corresponding cell culture. DNA was isolated from FFPE punches from tumor 
tissue (3 cylinders with a diameter of 0.6 mm) or a minimum of 10000 cultured cells using the Maxwell® 
16 DNA Purification Kits (Promega, Madison, WI). PCR and sequencing of VHL was performed as 
previously described (17). Fresh tissue samples were placed into sterile 50 mL conical tubes containing 
transport media (RPMI (Gibco, Waltham, MA) with 10 % fetal calf serum (FCS, Gibco) and Antibiotic-
Antimycotic® (Gibco). FFPE cell pellets from cultured cells were prepared as previously described (18) 
and compared to FFPE-specimens of the corresponding primary tumor by IHC. Cultures were 
maintained in K1 medium (19, 20) supplemented with 0.5 % FCS (Gibco) and Epinephrine (Sigma-
Aldrich, St. Louis, MO) and transferred into collagen I-coated cell culture dishes (Corning, NY) in a 
humidified incubator at 37 °C with 5% CO2. 
The ccRCC-derived 786-O cells which lack functional pVHL were supplied by American Type Culture 
Collection (ATCC) and cultured in RPMI-1640 (Sigma, R8758) with 10% fetal bovine serum (Gibco) 
and 100U/mL of penicillin and 100µg/mL streptomycin (Sigma-Aldrich). Stable transfectant of 786-O 
re-expressing pVHL-isoform 30 (786-O-VHL) was provided by Prof. Dr. Wilhelm Krek (ETH, Zurich), 
generated as described (21) and cultured using the same conditions as mentioned for 786-O. 0.5 mg/mL 
of G418 (Gibco, 10131) was used as selection antibiotic. Both cell lines were authenticated by 
authentication service of Microsynth (Balgach, Switzerland) and were previously used by our group (22, 
23).  
Human aortic endothelial cells (HAECs) from Cell Applications Inc (304-05a), were cultured in 
endothelial cell basal medium (LONZA Clonetics CC-3156) with 5% fetal bovine serum (GIBCO), 
100U/mL of penicillin and 100µg/mL streptomycin (Sigma-Aldrich), supplemented with singleQuots 
(LONZA Clonetics CC-4176 or ATCC PCS-100-041).  Hepatocellular carcinoma cells (Huh7) from 
JCRB (0403), and human renal proximal tubular epithelial cell line HK-2 (provided by R. Wüthrich 
Clinic for Nephrology, Department of Internal Medicine, University Hospital Zurich, Switzerland) were 
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cultured in Dulbecco’s Modified Eagle Medium (DMEM) with 10% fetal bovine serum (Gibco) and 
100U/mL of penicillin and 100µg/mL streptomycin (Sigma-Aldrich). 
Lipoprotein Isolation and labeling 
LDL (1.019<d<1.063 g/mL) and HDL (1.063<d<1.21 g/mL) were isolated from fresh normolipidemic 
plasma of blood donors by sequential ultracentrifugation as described previously (24, 25). LDL and 
HDL were radioiodinated with Na125I by the McFarlane monochloride procedure modified for 
lipoproteins (25, 26). Specific activities between 300-900 cpm/ng of protein were obtained.  
Lipoprotein cell association, pulse-chase and degradation assays 
All assays were performed in RPMI-1640 (Sigma) containing 25mmol/L HEPES and 0.2% BSA instead 
of serum (referred to as assay medium). Where indicated, cells were pre-treated with Sorafenib Tosylate 
(Selleckchem, 90nM) or Sunitinib Malate (Selleckchem, 80nM) for 30 minutes or with VEGF-A 
(Sigma, 25ng/mL) or anti-SR-BI neutralizing antibody (1:500, Novus NB400-113) or anti-IgG control 
(1:500, Santa Cruz-2027) for 1 hour at 37 ºC. Following treatments, the cells were incubated with 
10µg/mL of 125I-HDL or 125I-LDL in the absence or presence of a 40 times excess of non-labeled HDL 
and LDL respectively for 1 hour at 37ºC for association experiments. At the end of cell association step, 
the cells were washed twice with Tris- BSA buffer, followed by two washes with PBS containing CaCl2 
and MgCl2 and then lysed in 0.1N NaOH buffer. Specific cellular association was calculated by 
subtracting the values obtained in the presence of excess unlabeled HDL or LDL (unspecific) from those 
obtained in the absence of unlabeled HDL and LDL (total) respectively 
For pulse-chase experiments, 50,000 cells were seeded in 24 wells plates and cultured for 48 hours. 
Then the cells were pulsed for 1 hour with 10µg/mL of 125I-HDL or 125I-LDL at 37 ºC in the presence 
or absence of the respective unlabeled lipoprotein for competition and determination of specific 
interactions. After 1 hour of pulse incubation, the cells were either directly processed for the 
measurement of association or were washed three times with assay medium, chased for 1, 2 or 4 hours 
at 37 ºC with the assay medium containing 10μg/ml of unlabeled HDL or LDL. At the end of each chase 
period, the cells were handled as described above for the cellular association experiments. In addition, 
the media were collected and subjected to precipitation with trichloroacetic acid (TCA). Radioactivity 
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was counted by Perkin Elmer γ-counter. Precipitated radioactivity was postulated to reflect non-
degraded lipoproteins whereas radioactivity in the supernatant was considered to reflect degraded 
lipoproteins. (27). The amount of radioactivity in each fraction of the well (cell associated, TCA 
supernatant and TCA precipitated) was calculated by normalizing to the specific cellular association of 
the no chase of parental 786-O cells or primary ccRCC cells (represents initial radioactivity for the chase 
points). 
Real-time polymerase chain reaction 
Total RNA was isolated using TRI reagent (Sigma T9424) according to the manufacturer’s instruction. 
Genomic DNA was removed by digestion using DNase (Roche) and RNase inhibitor (Ribolock, Thermo 
Scientific).  Reverse transcription was performed using M-MLVRT (Invitrogen, 200U/µL) following 
the standard protocol as described by the manufacturer. Quantitative PCR was done with Lightcycler 
FastStart DNA Master SYBR Green I (Roche) using gene specific primers as mentioned in the 
Supplementary information.  
Small interfering RNA transfection 
786-O and 786-O-VHL cells were reverse transfected with small interfering RNA (Ambion silencer 
select, Life technologies) targeted to LDLR (s224006, s224007, s4) or VLDLR (siGENOME 
SMARTpool siRNA D-003721-02; ON-TARGET plus human VLDLR (7436), Dharmacon) or NRP1 
(s16844, s16843) or non-silencing control (4390843, silencer select or siGENOME control siRNA D-
001220-01-20, Dharmacon or ON-TARGET control siRNA D-01810-10-20, Dharmacon) at a final 
concentration of 5nmol/L using Lipofectamine RNA iMAX transfection reagent (Invitrogen, 13778150) 
in an antibiotic-free medium.  All experiments were performed 72 hours post-transfection and efficiency 
of transfection was confirmed with atleast two siRNAs against each gene using qRT-PCR.  
Western Blotting  
Cells were lysed in RIPA buffer (10mmol/L Tris pH 7.4, 150mmol/L NaCl, 1% NP-40, 1% sodium 
deoxycholate, 0.1% SDS, complete EDTA (Roche)) with protease inhibitors (Roche). Equal amounts of 
protein were separated on SDS-PAGE and trans-blotted onto PVDF membrane (GE Healthcare). 
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Membranes were blocked in appropriate blocking buffer recommended for the antibody (TBS-T 
supplemented with 5% milk) and incubated overnight on a shaker at 4 ºC with primary antibodies in the 
same blocking buffer. Membranes were incubated for 1 hour with an HRP-conjugated secondary 
antibody (Dako) in the blocking buffer. Membranes were further incubated with chemiluminescence 
substrate for 1min (Pierce ECL plus, Thermo scientific) and imaged using Fusion Fx (Vilber). The 
expression of LDLR (1:1000, ab30532, Abcam), VLDLR (1:1000, Novus, NBP1-78162), SR-BI 
(1:1000, NB400-131, Novus), NRP1 (1:1000, ab81321, Abcam) were evaluated and compared to the 
expression of either TATA binding protein (1:1000, TBP, ab51841, Abcam) which was used as a loading 
control. 
Cell surface expression analysis  
Biotinylation of intact cells was performed using 20mg/mL EZ-Link sulfo-NHS-S-S-Biotin (Thermo 
Scientific) in the cold for 1 hour with mild shaking and quenched with ice-cold 50mM Tris pH 7.4. Cells 
were lysed in RIPA buffer (total cell lysate) and 200-500µg of lysates were incubated with 20µL of 
BSA-blocked streptavidin beads suspension (GE Healthcare) for 16 hours at 4 ºC and pelleted by 
centrifugation; the pellet represents surface proteins. Proteins were dissociated from the pellet by boiling 
with SDS loading buffer and analyzed by SDS-PAGE and immunoblotted with SR-BI antibody (NB400-
131, Novus), TATA binding protein (TBP, ab51841, Abcam) used as intracellular control and Na+/K+-
ATPase (1:200, Santa Cruz-21712) used as cell surface control. 
Cell proliferation assay 
Cells were cultured at a density of 5000 cells per well in a 96 well plate for 72 hours. After transfecting 
with either siRNA against NRP1 or LDLR or non-silencing controls for 60 hours or blocking with SR-
BI neutralizing antibody for 1 hour, the cells were treated overnight with 50µg/mL of HDL or LDL.  
Following the overnight treatment, the supernatant was removed and cells were washed twice with PBS. 
The cells were then incubated with 30µL of MTT solution (5mg/mL in PBS,Sigma, M5655) diluted in 
270µL of DMEM for 30 minutes. The resultant formazan salts were extracted with dimethyl sulfoxide 
(DMSO) and absorbance intensity was read at 550nm and reference wavelength at 650nm (DMSO). The 
rate of cell proliferation is calculated relative to the 786-O parental cell line. 
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Statistical Analysis 
Contingency table analysis and Pearson’s chi-square tests were used to analyze the associations between 
protein expression patterns and clinical parameters. Overall survival rates were determined according to 
the Kaplan–Meier method and analyzed for statistical differences using a log rank test.  
The data sets for all in vitro experiments were performed with the GraphPad Prism 7.02 software. Data 
sets from independent experiments were pooled and the statistical tests were chosen based on the number 
of groups being compared (two or more than two). All the in vitro tests in this manuscript are based 
either on Mann-Whitney t-test or Kruskal-Wallis followed by Dunn’s post-test. Values are expressed as 
mean±s.e.m. P<0.05 was regarded as significant and P>0.05 was regarded as no significance. 
 
Results  
Lipoprotein and apolipoprotein expression and pathological parameters 
Immunostaining was performed on RCC tissue microarrays (TMA) for the major apolipoproteins of 
HDL and LDL, apolipoprotein A-I (apoA-I) and apolipoprotein B (apoB) respectively (Figures 1a and 
1b), as well as scavenger receptor BI (SR-BI, Figure 1c). Based on the staining intensities, expression 
levels in tumors were graded from 0 to 3 for apoA-I and SR-BI expression, and from 0 to 2 for apoB 
expression as staining intensities were generally lower. Increased immunoreactivity with anti-apoA-I or 
anti SR-BI antibodies but not immunoreactivity with anti-apoB antibodies significantly differentiated 
175 ccRCC tissues from papillary RCC (Table 1).  
Strong cytoplasmic apoA-I and SR-BI expression (staining intensity 2 and 3) was seen in approximately 
75% and 56% of ccRCC.  Moderate and weak cytoplasmic apoB expression was observed in 78% of 
ccRCC. This data indicates that the presence of apolipoproteins is characteristic in the majority of 
ccRCC (Table 1).  
We next evaluated the associations of the lipoprotein immunoreactivities in ccRCC with tumor stage 
(pT) and ISUP grade. Only anti-apoB-immunoreactivity was significantly associated with late tumor 
stage (Supplementary Table S3, P = 0.0371). apoA-I (P = 0.025) and apoB (P = 0.0006) but not SR-
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BI expression was significantly correlated with higher ISUP grade (Supplementary Table S4). We 
used the Kaplan-Meier method and log-rank test to evaluate any associations of apoA-I, apoB and SR-
BI immunoreactivity with overall survival (Supplementary Figure S1a-c). Only anti-apoA-I expression 
was significantly correlated with worse patient outcome (P = 0.0407, Supplementary Figure S1a). This 
association lost statistical significance upon multivariate analysis taking into account tumor stage and 
grade. 
Expression of apolipoproteins, SR-BI, and VHL downstream targets  
Loss of function of the VHL protein leads to stabilization of HIF- in ccRCC. Therefore, we statistically 
evaluated the associations of lipoprotein immunoreactivity with markers of the VHL/HIF axis, namely 
HIF-1α (Supplementary Table S5) and HIF-1α targets CA9 and GLUT1 (Supplementary Tables S6 and 
S7) as well as microvessel density recorded by CD34 abundance (Supplementary Table S8).  
Interestingly, the immunoreactivity for apoA-I showed significant positive associations with each of the 
four markers (HIF-1α: P = 0.0078; CA9: P = 0.0272; GLUT1: P = 0.0175 CD34: P < 0.001). ApoB 
immunoreactivity was significantly and positively associated with microvessel density (P = 0.0197) and 
nuclear HIF-1α staining (P = 0.0049). However, SR-BI immunoreactivity showed no significant 
association with any marker. 
ccRCC cells do not express apolipoproteins A-I and B but show enhanced uptake and impaired 
degradation and re-secretion of both HDL and LDL  
To unravel the origin of lipoprotein accumulation in ccRCC, we performed in vitro assays in two ccRCC 
cell lines which lack functional VHL (786-O and RCC4) and their stably transfected VHL wild-type 
counterparts (786-O-VHL, RCC4-O-VHL). To further corroborate our findings, we utilized patient-
derived ccRCC and normal epithelial kidney cell cultures that were established from surgical tissue 
specimens. Histological and genotypic comparison verified the resemblance of the patient-derived 
ccRCC and normal epithelial cell cultures to their respective primary human tissue. 
Immunohistochemistry of Pax8 and pan-Cytokeratin verified the renal epithelial origin of both PDC 
cultures while CAIX expression unequivocally confirmed the presence of malignant cells in the ccRCC 
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PDC culture (Supplementary Figure S2). Importantly, the ccRCC-derived cell culture retained the VHL 
driver mutation of the primary human tumor.   
We first analyzed by RT-PCR whether APOA1 and APOB are expressed by patient-derived ccRCC 
cells or the ccRCC cell lines. The hepatocellular derived carcinoma cell line Huh7 was used as positive 
control, human aortic endothelial cells (HAECs) served as negative control (Supplementary Figure 
S3a,b). Neither patient-derived ccRCC cells nor 786-O nor RCC4 showed any APOA1 and APOB 
transcripts (Supplementary Figure S3). However, we found both anti-apoA-I and apoB-
immunoreactivity in ccRCC tissue and patient-derived cell culture, possibly due to uptake from the 
serum containing cell culture media.   
Both, the patient-derived ccRCC cells culture and the VHL-deficient cell lines 786-O and RCC4 showed 
significantly higher specific cell association of 125I-HDL and 125I-LDL compared to the normal kidney 
epithelial cells and the re-transfected counterpart cell lines 786-O-VHL and RCC4-VHL: After 1 hour 
of incubation and compared to cultured normal epithelial kidney cells, association of 125I-HDL and 125I-
LDL were 50 to 100 %  and 80 to 150%  higher, respectively in the ccRCC-derived cell culture (first 
two columns of Figures 2a & 2b as well as Supplementary Figure S4a and b). The differences in cell 
association of 125I-HDL and 125I-LDL between 786-O and 786-O-VHL amounted to 40 to 200% and 70 
to 100% respectively (first two columns of Figures 3a & 3b as well as Supplementary Figure S4c and 
d). The association of 125I-HDL and 125I-LDL by RCC4 and RCC4-VHL even differed by factors 5 and 
10 respectively (Supplementary Figure S4e and f). This indicates that loss of pVHL correlates with 
increased lipoprotein uptake by ccRCC cells. 
To investigate whether the increased cellular association of 125I-HDL and 125I-LDL by VHL-deficient 
cells is caused by impaired degradation or re-secretion of the cell associated lipoproteins, a combination 
of pulse-chase and degradation experiments were performed with 125I-HDL and 125I-LDL. Already after 
1 hour chase, only 24% and 9% of the initially cell associated 125I-HDL and 125I-LDL, respectively, 
remained associated with cultured normal kidney epithelial cells. After 4 hours, both decreased 
significantly over prolonged chasing time to about 10% and 1% of the initial radioactivity, respectively. 
During prolonged chase, the percentage of degraded 125I-HDL increased to 70% at the expense of the 
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non-degraded which decreased to 15% (Figure 2a, Supplementary Figure S5a). Very strikingly, in the 
patient-derived ccRCC cell culture, the percentage of cell associated 125I-HDL was as high as 70% after 
1hour chase and did not decrease significantly over prolonged chase. The percentages of degraded 125I-
HDL increased over time so that after 4 hours chase no radioactivity was precipitated in the medium. At 
any time point of chase, the radioactivity of both degraded and non-degraded 125I-HDL was significantly 
lower in the patient-derived ccRCC compared to normal kidney cells (Figure 2a, Supplementary Figure 
S5a).  
The radioactivity of 125I-LDL in the medium of cultured normal kidney cells showed similar kinetics 
like that of 125I-HDL except that the proportion of non-TCA-precipitable radioactivity was higher 
already after 1 hour chase (60%) and increased to 80% after 4 hours chase. The proportion of the non-
degraded 125I-LDL decreased from 30% after 1 hour chase to 15% after 4 hours chase. Compared to 
patient-derived normal kidney cells, the ccRCC cell culture was significantly less active in degrading 
125I-LDL: the non-TCA-precipitable proportion of radioactivity was only less than 15% after 1 hour 
chase and increased to 25% after 4 hours chase. The relative difference in TCA-precipitable radioactivity 
between patient-derived normal kidney and ccRCC cells was significant but less prominent (Figure 2b, 
Supplementary Figure S5b).   
In principle, the same observations were made for the kinetics of 125I-HDL and 125I-LDL in a pulse chase 
experiment in the ccRCC cell lines 786-O and 786-O-VHL (Figure 3, Supplementary Figure S6): 786-
O-VHL cells showed considerable degradation of 125I-HDL and 125I-LDL as well as re-secretion of 125I-
HDL whereas the parental 786-O failed to degrade both 125I-HDL and 125I-LDL. The 786-O cells also 
showed a strongly reduced capacity to re-secrete 125I-HDL (Figure 3a&b, Supplementary Figure S6a, 
b). Together, these results indicate that the loss of VHL function in ccRCC cells increases lipoprotein 
uptake into a non-degrading non-secretory compartment. 
VEGF and NRP1 promote the cellular association of 125I-HDL and 125I-LDL in ccRCC  
As expected, the patient-derived ccRCC cell culture as well as 786-O and RCC4 cells showed higher 
VEGF mRNA expression compared to patient-derived normal kidney epithelial cells, 786-O-VHL and 
RCC4-O-VHL cells, respectively (Supplementary Figure S7). Pre-treatment with VEGF for 1 hour 
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increased the cellular association of both 125I-HDL as well as 125I-LDL in patient-derived normal 
epithelial kidney cells but not in ccRCC-derived cells (Figure 4a, b).  Similar observations were made 
in the ccRCC cell lines: The significantly lower cellular association of both 125I-HDL and 125I-LDL by 
786-O-VHL and RCC4-O-VHL cells was increased by pre-treatment with VEGF for 1 hour to the same 
level as observed in 786-O (Figure 4c, d) and RCC4 cells (Supplementary Figure S8a,b), respectively, 
with or without treatment with VEGF. Further, supporting the crucial role of VEGF, pre-treatment of 
786-O cells with VEGF receptor inhibitors for 30 minutes decreased specific cellular association of both 
125I-HDL and 125I-LDL but had no effect in 786-O-VHL cells (Supplementary Figure S9a-d).  
Interestingly, ccRCC cells expressed neither VEGFR1 nor VEGFR2 nor VEGFR3, but expressed 
neuropilin-1 (NRP1) which is a co-receptor of VEGFR (Supplementary Table S9). To test whether 
NRP1 mediates the effects of VEGF on the cellular association of radioiodinated lipoproteins in vitro, 
we targeted NRP1 using RNAi in 786-O and 786-O-VHL cells (Supplementary Figure S10a, b). 
Silencing of NRP1 led to decreased specific cellular association of 125I-HDL as well as 125I-LDL in both 
786-O and 786-O-VHL cells. Interestingly, pre-treatment with VEGF for 1 hour stimulated the specific 
cellular association of neither 125I-HDL nor 125I-LDL in 786-O-VHL cells in which NRP1 was knocked-
down (Figure 5a-d). In conclusion, VEGF/NRP1 mediated signaling stimulates the uptake of 125I-HDL 
as well as 125I-LDL in ccRCC. 
SR-BI but neither LDLR nor VLDLR mediates cellular association of 125I-HDL and 125I-LDL in 
ccRCC 
We next aimed to unravel which receptor enhances the lipoprotein uptake by ccRCC cells. We first 
assessed the expression of candidate receptors, LDLR, VLDLR and SR-BI in vitro. We found lower 
expression of LDLR in the 786-O cells compared to 786-O-VHL (Supplementary Figure S11a). By 
contrast, total lysates of 786-O and 786-O-VHL cells did not differ in SR-BI or VLDLR protein levels 
(Figure 6a and Supplementary Figure S12a). However, cell-surface biotinylation revealed strongly 
increased expression of SR-BI on the cell surface of parental 786-O cells compared to that of 786-O-
VHL cells (Figure 6a). Knock-downs of LDLR and VLDLR by RNA interference efficiently suppressed 
protein abundance of LDLR and VLDLR, respectively (Supplementary Figures S11b, S12a), but did not 
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affect the cellular association of iodinated lipoproteins (Supplementary Figures S11c, S12b,c). By 
contrast in both 786-O and 786-O-VHL cells, the specific cellular association of 125I-HDL as well as 
125I-LDL was significantly decreased in the presence of a neutralizing anti-SR-BI-antibody (Figures 
6b,c). The neutralizing anti-SR-BI-antibody also decreased the cellular association of 125I-HDL and 125I-
LDL by RCC4 and RCC4-O-VHL cells (Supplementary Figure S13a,b) as well as in  patient-derived 
ccRCC and normal kidney epithelial cell cultures (Figure 7a, b). Taken together, these results indicate 
that the uptake of HDL and LDL by ccRCC cells depends on the cell-surface expression of SR-BI. 
NRP1 and SR-BI mediate LDL-dependent proliferation of ccRCC cells 
We finally investigated whether the excess cellular association and accumulation of lipoproteins 
contributed to the proliferation of ccRCC cells. We found higher proliferation of 786-O cells compared 
to 786-O-VHL, indicating that loss of VHL function increases proliferation in ccRCC cells (Figure 8a). 
Interestingly, pretreatment with LDL but less so HDL increased the proliferation of both ccRCC cell 
lines (Figure 8b). Basal as well as lipoprotein-stimulated proliferation was reduced in both 786-O- and 
786-O-VHL cells by knock-down of NRP1 (Figure 8c and Supplementary Figure S14a). Both in the 
presence and absence of lipoproteins and in both 786-O and 786-O-VHL cells (Supplementary Figures 
S14b-d) the proliferation was significantly decreased by the neutralization of SR-BI (Figure 8d, 
Supplementary Figure S14b) but not by knock-down of LDLR (Supplementary Figures S14c, d). 
Together, these results indicate that LDL promotes the proliferation of ccRCC cells in a NRP1- and SR-
BI- but not LDLR-dependent manner.   
Discussion 
By combining immunohistochemical studies of renal carcinomas with functional experiments in three 
ccRCC cell culture models we made several important findings on the as yet little understood 
mechanism and pathogenic role of intracellular lipid accumulation in ccRCC. First, the 
immunochemical investigation of apoA-I and apoB in renal carcinomas revealed that ccRCCs store 
lipoproteins rather than lipids per se. Second, our functional comparisons of a patient-derived ccRCC 
with a normal epithelial kidney cell culture as well as two VHL-defective ccRCC cell lines (786-O and 
RCC4) with VHL-intact derivative cell lines (786-O-VHL and RCC4-VHL, respectively) identified 
 at UZH Hauptbibliothek / Zentralbibliothek Zuerich, on Septem
ber 14, 2018
w
w
w
.jlr.org
D
ow
nloaded from
 
15 
 
enhanced uptake of LDL and HDL and subsequent impairment of degradation and re-secretion as the 
likely mechanism leading to intracellular lipid accumulation in ccRCC. Third, SR-BI was identified as 
the rate limiting lipoprotein receptor for the association of both HDL and LDL by ccRCC cells. Fourth 
VEGF, which is highly expressed by ccRCCs was found to promote the association of lipoproteins by 
ccRCC cells through activation of its non-canonical receptor NRP1. Fifth, LDL was found to promote 
ccRCC cell proliferation in a SR-BI- and NRP1- dependent manner.  
The intracellular storage of LDL is very unusual because the internalization of LDL into other cells, 
notably hepatocytes, macrophages but also renal mesangial or tubular cells, is followed by degradation 
(27-29). Most cells internalize LDL via the LDL-receptor into clathrin-coated pits (30, 31). LDL is then 
trafficked into an endosomal/lysosomal route, depending on the presence or absence of PCSK9 either 
together or separated from the receptor (32, 33). The apoB moiety and cholesteryl esters of LDL are 
hydrolyzed by lysosomal proteases and acid lipase, respectively (34-36). In hepatocytes and 
macrophages but also other cells, any cholesteryl ester storage in lipid droplets results from the re-
esterification of cholesterol in the ER after transfer from the lysosomes (37). The intracellular storage 
of endocytosed holoparticles hence argues against any role of LDLR for lipid storage in ccRCC. In fact, 
we confirmed the finding of others that LDLR is suppressed in ccRCC and ruled out by RNA 
interference that LDLR contributes to LDL or HDL association by ccRCC cells (Supplementary Figure 
S11).  Internalization of apoB-containing lipoproteins by other members of the LDL receptor family, 
for example LRP1, LRP2, or VLDL receptor into a broad variety of cells  is also followed by lysosomal 
degradation of both their proteins and lipids (38). Interestingly, the VLDL receptor was previously 
reported to be up-regulated in ccRCC and to promote lipid uptake into ccRCC cells. However, this study 
only recorded the uptake of VLDL-derived lipids rather than the lipoproteins’ protein moiety (5). We 
found no difference in the expression of VLDLR between the ccRCC cell line 786-O and its VHL-
expressing counterpart 786-O-VHL. Moreover, our siRNA experiments ruled out that VLDLR 
contribute to the uptake of LDL or HDL by ccRCC (Supplementary Figure S12) 
The most likely reason for the unusual lipoprotein storage by ccRCC cells is the involvement of SR-BI. 
We, like others (5, 6, 39), found strong immunoreactivity of SR-BI in ccRCC but not in other renal 
tumors. Interestingly, Xu et al. previously reported a reduced content of HDL-cholesterol in 786-O cells 
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which were treated with siRNA against SR-BI (6). We here extend these previous findings by showing 
that the inhibition of SR-BI prevents the uptake of LDL as well as HDL into patient-derived cultured 
ccRCC cells as well as into the 786-O and RCC4 cell lines (Figure 6b,c & Figure 7a,b). The mechanism 
by which SR-BI promotes cellular lipoprotein uptake is not clear: SR-BI is traditionally regarded as a 
receptor which binds both HDL as well as LDL and provides bidirectional fluxes of cholesterol from 
these lipoproteins into cells or from the plasma membrane to the lipoprotein depending on the 
concentration gradient (40, 41). However, several examples have been reported where ablation or 
blockage of SR-BI also inhibited the uptake of lipoprotein particles. Notably, vascular endothelial cells 
were reported by our and other laboratories to internalize and transcytose HDL and LDL in an SR-BI 
dependent manner (42, 43). However, it is not clear whether SR-BI or one of its splice variants directly 
serve as an endocytic receptor (44, 45) or whether SR-BI only enables other pathways of endocytosis. 
Such indirect effects of SR-BI may include the activation of other receptors by altering the cholesterol 
distribution within the plasma membrane or signaling via its PDZ domain (46). SR-BI mediated 
endocytosis of HDL and LDL into endothelial cells is followed by re-secretion and hence allows 
transcytosis of lipoproteins, for example from the blood stream into the arterial wall or into the brain as 
well as from the extravascular tissue into the lymph (13, 47, 48). Interestingly, we here found that a 
patient-derived ccRCC cell culture as well as the VHL-deficient 786-O and RCC4 cell lines not only 
fail to degrade but also to re-secrete the internalized lipoproteins, notably HDL.  
VEGF signaling, activated by loss of VHL function, appears to be the reason for the enhanced SR-BI 
mediated uptake of HDL and LDL into ccRCC cells: Compared to VHL-proficient cultured normal 
kidney cells, 786-O-VHL and RCC4-VHL cells, the VHL-deficient ccRCC-derived cell culture ,786-O 
and RCC4 cells show increased expression of VEGF (Supplementary Figure S7a-c). Pre-treatment with 
VEGF increased the uptake of both HDL and LDL by normal kidney cells as well as VHL re-transfected 
cells which are characterized by low endogenous VEGF expression but neither by the patient-derived 
ccRCC cell culture nor 786-O or RCC4 cells which already express high amounts of VEGF (Figure 4a-
d, Supplementary Figure S8a, b). Conversely, lipoprotein uptake was lowered in 786-O cells by VEGFR 
inhibitors (Supplementary Figure S9a-d). These findings are in line with the previous report of HIF-1α 
-dependent lipid uptake into ccRCC (6). They are also in line with our previous observation in HAECs 
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where VEGF promoted the translocation of SR-BI to the cell membrane as well as the uptake and 
transcytosis of HDL (13). In this regard it is noteworthy to reconcile the significant correlation of 
VHL/HIF-1α downstream targets (Glut1 and CAIX) with immunoreactivity of both apoA-I and apoB, 
suggesting that increased cellular apoA-I and apoB levels are a consequence of VHL/HIF-1α signaling 
activation. Activated VEGF signaling in ccRCC due to increased HIF-1α activity may enhance 
lipoprotein uptake into the tumor not only by direct actions on tumor cells but also indirectly by 
promoting their transport from the circulation into the tumor tissue. VEGF is known to activate the 
downstream signaling by binding to VEGF receptors (49). However, we did not detect the expression 
of any of the three VEGF receptors in the ccRCC cells (Supplementary Table S9). Importantly, in line 
with previous findings (50), we detected higher expression of NRP1 in the VHL lacking 786-O cells 
compared to the wild type VHL expressing 786-O-VHL cells. Upon binding of VEGF, NRP1 elicits 
angiogenesis and tumorigenesis both dependently and independently of VEGF receptors. The enhanced 
uptake of HDL and LDL in 786-O-VHL cells by pre-treatment with VEGF was abrogated by the 
suppression of NRP1 (Figure 5). Altogether, our findings identify a novel role of NRP1 in the cholesterol 
accumulation of ccRCC. 
Our observations provide a plausible explanation for the origin of lipid accumulation in ccRCC. 
However, they do not allow any conclusion on whether or not enhanced lipoprotein uptake into ccRCC 
has any impact on the clinical course of this disease. Excessive lipids in cancer cells are considered as 
markers of cancer aggressiveness (51). In line with this, immunoreactivity for apoA-I, apoB, or SR-BI 
was associated with the differentiation of renal carcinomas into ccRCC as well as with tumor grade 
(apoA-I and apoB) or tumor stage (apoB). However, expression of apoB or SR-BI showed no association 
with prognosis. By contrast, apoB and apoA-I immunoreactivities were associated with lower tumor 
stage and better survival, respectively (Supplementary Table S3 and Supplementary Figure S1). 
Previously, in two Chinese studies each encompassing about 100 patients, SR-BI protein and mRNA 
expression were found associated with the prognosis of ccRCC (6, 52). We did not replicate this 
observation in our larger cohort of 172 patients. However, it is important to note, that in our in vitro 
experiments the cell surface expression of SR-BI rather than the total SR-BI content was dependent of 
VHL and VEGF. The semi-quantitative scoring of immunostaining intensity does however not 
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discriminate between the larger pool of intracellular SR-BI from the smaller pool of cell surface SR-BI. 
Interestingly, genome-wide association studies identified a borderline significant association of the 
rs4765623 polymorphism in SCARB1 with ccRCC susceptibility (53) indicating a pathogenic role of 
SR-BI in ccRCC. In line with an oncogenic role, knock down of SR-BI was found to inhibit proliferation 
(Figure 9, ref (6)), colony formation, migration and invasion of ccRCC cells as well as expression and 
phosphorylation of Akt (6). SR-BI has also been associated with carcinogenic features in breast cancer, 
prostate cancer, and melanoma (54, 55).  
In conclusion, we identified SR-BI mediated intracellular accumulation of intact lipoproteins as the 
likely origin of cholesterol accumulation and the characteristic clear cytoplasm of ccRCC. VEGF 
induced SR-BI cell surface translocation may be the underlying mechanism and the resulting enhanced 
SR-BI/lipoprotein interaction may contribute to proliferation and hence prognosis of ccRCC. 
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Table 1 
Protein of 
interest 
Staining 
intensity 
Subtype 
Clear-cell RCC Chromophobe Papillary 
a
p
o
A
-I
 
0 (n) 5.1% (9) 0 12% (3) 
1 (n) 18.9% (33) 50% (3) 44% (11) 
2 (n) 24.6% (43) 16.7% (1) 32% (8) 
3 (n) 51.4% (90) 33.3% (2) 12% (3) 
a
p
o
B
 
0 (n) 21.7% (38) 16.7% (1) 24% (6) 
1 (n) 62.3% (109) 50% (3) 68% (17) 
2 (n) 16% (28) 33.3% (2) 8% (2) 
S
R
-B
I 
0 (n) 18.7% (31) 80% (4) 78.9% (15) 
1 (n) 25.3% (42) 20% (1) 10.5 (2) 
2 (n) 27.7% (46) 0 5.3 (1) 
3 (n) 28.3% (47) 0 5.3 (1) 
 
Table 1: Quantification of apolipoproteins and SR-BI expression in renal cell carcinoma TMA 
Percent and absolute (n = number) frequencies of anti-apoA-I, anti-apoB and anti-SR-BI staining 
intensities among renal cell carcinoma subtypes. 
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Figure 1 
 
 
 
Figure 1: Apolipoprotein and SR-BI expression in renal cell carcinoma TMA Immunostaining of 
a, apoA-I b, apoB and c, SR-BI of human tissue microarrays. The grading from 0-3 represents the 
staining intensity from negative to the strongest.  
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Figure 2 
 
 
Figure 2 Cellular association, resecretion and degradation of 125I-HDL and 125I-LDL in patient-
derived ccRCC and normal kidney epithelial cell cultures.  Both ccRCC- and normal kidney derived 
cells were pulsed for 1 hour with 10µg/mL of either a, 125I-HDL or b, 125I-LDL at 37ºC in the absence 
(total) or in the presence of 40-fold excess of unlabeled HDL or LDL (unspecific). Subsequently, the 
cells were either lysed and analyzed for their content of radiolabel or chased for 1,2 and 4 hours with 
unlabeled HDL or LDL at 37ºC. The media were collected and subjected to precipitation with TCA to 
count radioactivity of non-degraded /resecreted lipoproteins in the precipitate and degraded lipoproteins 
in the supernatant separately. Specific association was calculated by subtracting unspecific values from 
total values. The amount of radioactivity in each fraction of the well (cell associated, TCA supernatant 
and TCA precipitated) was calculated by normalizing to the specific cellular association of the no chase 
of ccRCC cells (represents initial radioactivity for the chase points). The results are represented as 
mean±s.e.m of two independent experiments, with two batches of 125I-HDL and 125I-LDL. Significance 
is determined for each fraction at each time point using by Mann-Whitney test. For specific cell 
associated: *** P≤ 0.001. For TCA supernatant: ●●●P≤ 0.001, ●●P≤ 0.01, ●P≤ 0.05. For TCA 
precipitated: †† P≤ 0.01, †P≤ 0.05. n.s represents “not significant”. 
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Figure 3 
 
                   
Figure 3: Cellular association, re-secretion and degradation of 125I-HDL and 125I-LDL in 786-O 
and 786-O-VHL cells.   The results are represented as mean±s.e.m of two independent experiments, 
with two batches of 125I-HDL and 125I-LDL which were performed as described in the legend of Figure 
2. Significance is determined for each fraction at each time point using by Mann-Whitney test. For 
specific cell associated: *** P≤ 0.001, ** P≤ 0.01. For TCA supernatant: ●●●P≤ 0.001, ●●P≤ 0.01. For 
TCA precipitated: †P≤ 0.05. n.s represents “not significant”. 
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Figure 4 
              
 
Figure 4: Loss of VHL promotes cellular association of 125I-HDL and 125I-LDL in ccRCC cells 
Patient-derived ccRCC and normal epithelial kidney cell cultures, 786-O and 786-O-VHL cells were 
pre-treated with 25ng/mL of VEGF for 1 hour prior to assays, followed by incubation with 10µg/mL of 
a, c 125I-HDL or b, d 125I-LDL at 37 ºC for 1 hour in the absence (total) or in the presence of 40-fold 
excess of unlabeled HDL or LDL (unspecific). Specific cellular association was calculated by 
subtracting unspecific values from total values. The results are represented as mean±s.e.m of three 
independent experiments (in triplicates, triplicates and duplicates respectively) for cell lines and two 
independent experiments with patient-derived cells, with two batches of 125I-HDL and 125I-LDL. 
Significance is determined by Kruskal-Wallis test followed by Dunn’s post-test. ***P≤ 0.001, **P≤ 
0.01, *P≤ 0.05. 
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Figure 5 
 
 
Figure 5: NRP1 promotes cellular association of 125I-HDL and 125I-LDL in renal carcinoma 786-
O cells 786-O and 786-O-VHL cells were transfected with specific siRNA against NRP1 or with non-
silencing control siRNA (NS control). After 72 hours of transfection, the cells were pre-treated with 
25ng/ml of VEGF for 1 hour prior to assays as indicated, followed by incubation with 10µg/mL of 125I-
HDL or 125I-LDL. 786-O cells incubated with a, 125I-HDL b, 125I-LDL. 786-O-VHL cells incubated with 
c, 125I-HDL d, 125I-LDL at 37 ºC for 1 hour in the absence (total) or in the presence of 40-fold excess of 
unlabeled HDL or LDL (unspecific). Specific cellular association was calculated by subtracting 
unspecific values from total values. The results are represented as mean±s.e.m of three independent 
experiments (each experiment in triplicates), with two batches of 125I-HDL and 125I-LDL. Significance 
is determined by Kruskal-Wallis test followed by Dunn’s post-test. ***P≤ 0.001, **P≤ 0.01, †††P≤ 
0.001, ††P≤ 0.01. 
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Figure 6        
  
 
Figure 6: SR-BI mediates cellular association of 125I-HDL and 125I-LDL in 786-O cells a, Cell 
surface expression of SR-BI in renal carcinoma cells. Western blot analysis of SR-BI in total cell lysates 
(left) and on the cell surface (right) in 786-O and 786-O-VHL cells. The western blots were probed with 
anti-SR-BI (82kDa) and anti-TBP (40kDa, used as a control for intracellular protein expression), anti 
Na+/K+-ATPase (110kDa, used as a control for cell surface protein expression). 786-O and 786-O-VHL 
cells were pre-treated with either anti-SR-BI neutralizing antibody or isotype (IgG) control for 1 hour 
prior to assays, followed by incubation with 10µg/mL of b, 125I-HDL or c, 125I-LDL for 1 hour in the 
absence (total) or in the presence of 40-fold excess of unlabeled HDL or LDL (unspecific) at 37 ºC. 
Specific association was calculated by subtracting unspecific values from total values. The results are 
represented as mean±s.e.m of three independent experiments (each experiment in triplicates) with two 
batches of 125I-HDL and 125I-LDL. Significance is determined by Kruskal-Wallis test followed by 
Dunn’s post-test. IgG control represents isotype control and anti-SR-BI Nab represents treatment with 
SR-BI neutralizing antibody. **P≤ 0.01, †P≤ 0.05. Complete blots in Supplementary Electrophoretic 
Blot A. 
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Figure 7 
 
Figure 7: SR-BI mediates cellular association of 125I-HDL and 125I-LDL in ccRCC cells Both the 
patient-derived ccRCC and normal epithelial kidney cell cultures were pre-treated with either anti-SR-
BI neutralizing antibody or isotype (IgG) control for 1 hour prior to assays, followed by incubation with 
10µg/mL of a, 125I-HDL or b, 125I-LDL for 1 hour in the absence (total) or in the presence of 40-fold 
excess of unlabeled HDL or LDL (unspecific) at 37 ºC. Specific association was calculated by 
subtracting unspecific values from total values. The results are represented as mean±s.e.m of two 
independent experiments (each experiment in triplicates) with two batches of 125I-HDL and 125I-LDL. 
Significance is determined by Kruskal-Wallis test followed by Dunn’s post-test. IgG control represents 
isotype control and anti-SR-BI Nab represents treatment with SR-BI neutralizing antibody. *P≤ 0.05, 
†P≤ 0.05. 
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Figure 8 
 
Figure 8: Effects of VHL, HDL, LDL, NRP1 and SR-BI on proliferation of ccRCC cells. VHL-
defective 786-O and VHL-intact 786-O-VHL cells were cultured in a 96 well plate for 60 hours prior to 
the overnight treatment with 50µg/mL of HDL or LDL. The rate of proliferation was analyzed using the 
MTT assay. a, comparison of 786-O and 786-O-VHL cells per se b, in the presence or absence of 
50µg/mL of either HDL or LDL. 786-O cells were transfected with c, specific siRNA against NRP1 or 
with non-silencing control siRNA (NS control) for 60 hours or d, pre-treated with a neutralizing antiSR-
BI antibody for 1 hour prior to the overnight treatment with 50µg/mL of HDL or LDL. The results are 
represented as mean±s.e.m of three independent experiments with two batches of HDL and LDL. 
Significance is determined by Kruskal-Wallis test followed by Dunn’s post-test. IgG control represents 
isotype control and anti-SR-BI Nab represents treatment with neutralizing anti-SR-BI antibody. ***P≤ 
0.001, **P≤ 0.01, *P≤ 0.05. †††P≤ 0.001, ††P≤ 0.01, †P≤ 0.05 and ns represents “not significant”. 
 
 at UZH Hauptbibliothek / Zentralbibliothek Zuerich, on Septem
ber 14, 2018
w
w
w
.jlr.org
D
ow
nloaded from
 
